Treatment of Secondary Erythema Nodosum in Behçet Disease

When erythema nodosum arises as a manifestation of Behçet disease, the underlying neutrophilic inflammatory process shapes the choice of therapy. The clinical target is resolution of tender erythematous nodules on the lower extremities.

Clinical Scenario

Secondary erythema nodosum in a patient with Behçet disease. The neutrophilic dermatotic nature of EN in this setting distinguishes it from other secondary forms and determines which agents have the strongest evidence base.

Treatment Goal

Resolution of tender erythematous nodules on the lower extremities.

Treatment Approach (Partial Overview)

First-line management draws on specific oral agents with established activity against neutrophilic dermatoses—a class of drugs that have been used mainly in EN occurring in the context of Behçet disease. Full agent selection, dosing guidance, and clinical sequencing are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-021-00592-w

Colchicine at 1–2 mg/day, adjusted to body weight, has been used mainly in patients with EN and Behçet disease.

Potassium iodide, colchicine, and dapsone are drugs used for treating neutrophilic dermatosis, making them a good option for EN associated with Behçet disease.

View source ↗